Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

NCT00111475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Thrombocytopenic Purpura

Interventions

DRUG: Romiplostim
DRUG: Placebo

Sponsor

Amgen